ClinicalTrials.gg
CompletedNCT07716358Updated Jul 21, 2026

Comparison Of Preoperative Ultrasound Guided Fascia Iliaca Block Versus Femoral Nerve Block for Proximal Femur Fractures Before Positioning for Spinal Anaesthesia

An interventional study of Femoral Nerve Block and Fascia Iliaca Nerve Block in Proximal Femur Fractures and Nerve Block Assessment, sponsored by Sahara Medical College Narowal Pakistan. Completed at 1 site in Pakistan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Sahara Medical College Narowal Pakistan · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

Proximal femur fractures are among the most painful orthopedic injuries Adequate analgesia is essential to facilitate positioning for spinal anesthesia, reduce opioid requirements, and minimize related complications. The aim of study to compare the analgesic efficacy of preoperative ultrasound-guided Fascia Iliac Block Versus and Femoral Nerve Block in patients with proximal femur fractures prior to positioning for spinal anesthesia.

02

Conditions studied

  • Proximal Femur Fractures
  • Nerve Block Assessment

Keywords

  • Femoral Nerve block
  • Fascia Iliac Compartment Block
  • visual analogue scale
03

In context

Proximal Femoral Fractures

36 studies on the registry are indexed under Proximal Femoral Fractures; 6 are open to participants now.

This study's enrollment of 84 is above the median of 68 across 22 interventional studies indexed under Proximal Femoral Fractures.

Browse Proximal Femoral Fractures studies →

Lead sponsor

This is the only study on the registry with Sahara Medical College Narowal Pakistan as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \&II status patients coming for proximal femur fracture surgery

Exclusion criteria

Exclusion Criteria:

  • Patients with history of neurological disease (Alzheimer, dementia),
  • Patients with known to regional anaesthesia (e.g., signs of infection at site of block, coagulation abnormality i.e. >1.55, count \<80,000)
  • Patients with and IV status and patients with Known allergy to the study drug were excluded from study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Group A Participants who received Ultrasound Guided Femoral Nerve Block

    Participants in group-A were 42 which were assigned randomly and Femoral Nerve Block was done before spinal anaesthesia.

    Procedure: Femoral Nerve Block

  • Active comparator
    Group B Participants who received Ultrasound Guided Fascia Iliaca Block

    Participants in group- B were 42 which were assigned randomly and Fascia Iliaca Block was done before spinal anaesthesia.

    Procedure: Fascia Iliaca Nerve Block

Interventions

  • ProcedureFemoral Nerve Block

    FNB was carried out as follows: the linear probe was kept in a "in line plane" approach to identify the femoral artery under ultrasound guidance. The triangular, hyperechoic femoral nerve was identified as being situated lateral to the femoral artery. The femoral artery was positioned next to an insulated 22 G needle. Once the needle tip was located and a negative blood aspiration was obtained, a little amount of local anesthetic (injection bupivacaine 0.25%) was administered. The remaining drug volume was injected based on weight (0.5 ml/kg) once the local anesthetic distribution was observed

  • ProcedureFascia Iliaca Nerve Block

    The FICB was administered as described. We found the psoas muscle lateral to the femoral nerve. The iliacus fascia, which extends deep into the fascia Lata, covers it. Consequently, a double pop was felt after inserting the needle until it was between the psoas muscle and the fascia iliaca. As with the previously described method, 1 mL of the local aesthetic solution was injected, and following a negative blood aspiration, the medication disseminated beneath the fascia iliaca.

06

What researchers measure

Primary outcomes

  1. Pain Control

    In patients with proximal femur fractures pain assessment was done baseline before blocks and at five minutes after blocks administration. Pain control assessment was done based on Visual Analogue Scale from 0-10.

    Time frame: 05 minutes

07

Study locations

1 site
  • Sughra Shafi Medical Complex
    Chak Ninety-five North Branch, Punjab Province 51600, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Jun 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 21, 2026
StartActual
Jan 1, 2026
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07716358
Lead sponsor
Sahara Medical College Narowal Pakistan
Responsible party
Dr Rafia Kousar (Principal Investigator, Sahara Medical College Narowal Pakistan) — Principal investigator
First posted
Jul 21, 2026
Start date
Jan 1, 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion